Browsing Tag
Immutep
5 posts
TACTI-004 investigation gives Immutep a possible explanation as efti prepares for 2027 restart
Immutep finds efti manufacturing differences after TACTI-004 and refocuses development on head and neck cancer and soft tissue sarcoma.
Immutep (NASDAQ: IMMP) jumps 15% as efti review points to manufacturing differences
Immutep has identified potentially relevant structural differences between 200-litre and 2,000-litre efti manufacturing batches after the TACTI-004 failure, prompting a return to 200-litre production and a narrower clinical strategy.
Immutep (ASX: IMM) surges 48% on FDA orphan drug designation: Is the STS pivot the new thesis?
Immutep (ASX: IMM) jumped 48% after the FDA granted orphan drug status for eftilagimod alfa in soft tissue sarcoma. Here is what the EFTISARC-NEO data means for the investment case.
Immutep reports positive Phase IIb results for Eftilagimod Alfa in head and neck cancer treatment
Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company, has announced encouraging results from Cohort B of…
Immutep taps Charles River for IMP761 LAG-3 antibody preclinical study
Immutep Limited, an Australian biotech company specializing in LAG-3 immunotherapies for cancer and autoimmune diseases, has partnered with…